Skip to main content Skip to accessibility
This website is not compatible with your web browser. You should install a newer browser. If you live in Jersey and need help upgrading call the States of Jersey web team on 440099.
Government of Jerseygov.je

Information and public services for the Island of Jersey

L'înformâtion et les sèrvices publyis pouor I'Île dé Jèrri

Changes to be made to the Prescribed List (Jersey) as at 1 October 2008.

A formal published “Ministerial Decision” is required as a record of the decision of a Minister (or an Assistant Minister where they have delegated authority) as they exercise their responsibilities and powers.

Ministers are elected by the States Assembly and have legal responsibilities and powers as “corporation sole” under the States of Jersey Law 2005 by virtue of their office and in their areas of responsibility, including entering into agreements, and under any legislation conferring on them powers.

An accurate record of “Ministerial Decisions” is vital to effective governance, including:

  • demonstrating that good governance, and clear lines of accountability and authority, are in place around decisions-making – including the reasons and basis on which a decision is made, and the action required to implement a decision

  • providing a record of decisions and actions that will be available for examination by States Members, and Panels and Committees of the States Assembly; the public, organisations, and the media; and as a historical record and point of reference for the conduct of public affairs

Ministers are individually accountable to the States Assembly, including for the actions of the departments and agencies which discharge their responsibilities.

The Freedom of Information Law (Jersey) Law 2011 is used as a guide when determining what information is be published. While there is a presumption toward publication to support of transparency and accountability, detailed information may not be published if, for example, it would constitute a breach of data protection, or disclosure would prejudice commercial interest.

A decision made (12/09/2008) regarding: Changes to be made to the Prescribed List (Jersey) as at 1 October 2008.

Decision Reference: MD-S-2008-0048

Decision Summary Title :

Prescribed List (Jersey) 1 October 2008

Date of Decision Summary:

14/8/08

Decision Summary Author:

R. Goulding

Policy Principal

Decision Summary:

Public or Exempt?

Public

Type of Report:

Oral or Written?

Written

Person Giving

Oral Report:

 

Written Report

Title :

Changes to be made to the Prescribed List (Jersey) as at 1 October 2008

Date of Written Report:

14/8/08

Written Report Author:

R. Goulding

Policy Principal

Written Report :

Public or Exempt?

Public

Subject:

Changes to be made to the Prescribed List (Jersey) as at 1 October 2008

Decision(s): The Minister approved the changes to the Prescribed List (Jersey) as recommended by the Pharmaceutical Benefits Advisory Committee from the meeting held on the 15 July 2008.

To be included:  

  1. 5 items to be included from October 2008  - Please refer to attachment (appendix 1)

To be deleted

  1. 3 items to be deleted from 31 December 2008 – Please refer to attachment (appendix 2)
  2. ii.         23 items to be listed as generic only from 1 January 2009 - Please refer to attachment (appendix 3)

Reason(s) for Decision:

The Pharmaceutical Benefits Advisory Committee met on 15 July 2008 and provided the Minister with the recommended changes to the Prescribed List (Jersey), effective from 1 October 2008.

The changes included ongoing work to update the list by removing discontinued preparations as well as revision of 22 items to generic formulations only.

Resource Implications:

The Fund has sufficient resources.

Action required:

The Minister approved the recommendations made by the Pharmaceutical Benefits Advisory Committee for implementation on 1 October 2008.

Signature: 

Position: 

Date Signed: 

Date of Decision (If different from Date Signed): 

Changes to be made to the Prescribed List (Jersey) as at 1 October 2008.

Recommendations of the Pharmaceutical benefit Advisory Committee

July 2008  
 

1. SUMMARY  

The Pharmaceutical Benefit Advisory Committee met on 15th July 2008 to consider the inclusion and/or deletion of certain products from the Prescribed List. The PBAC recommended the inclusion of 5 products, the deletion of 3 products detailed in this report. This report also includes work to update the list by removing discontinued preparations and revision of 22 items to generic formulations only. 

 

  1. BACKGROUND

Items for inclusion 

2.1. Ondansetron tablets 4mg, 8mg/oral lyophilisates; injection 4mg/2mL, 8mg/4mL (Green drug)

This is a 5-HT3 antagonist licensed for the prevention and treatment of nausea and vomiting associated with surgery or emetogenic radiotherapy or chemotherapy. The approval is specifically for restricted, short-term use (no more than 5 days) in patients with terminal illness and intractable nausea/vomiting. 

2.2. Co-codamol effervescent tablets 8/500mg (Green drug)

This is a non-opioid analgesic that is licensed for the treatment of mild to moderate pain and pyrexia. The approval must be specifically for generic only formulation. 

2.3. Losartan tablet 100mg (Green drug)

This is a Angiotensin-II receptor antagonist that is licensed for the treatment of hyper tension (including reduction of stroke risk in hypertension with left ventricular hypertrophy); diabetic nephropathy in type 2 diabetes mellitus.  

The patent for losartan expires in September 2009 and the annual cost for Losartan 100mg daily is £211. In comparison, the annual costs of the alternatives available on the list are:  

Losartan 50mg tablet  £167

Losartan 25mg tablet  £211 
 

2.4. Novolizer budesonide 200mcg inhalation powder; Salbulin (salbutamol) MDPI Novolizer 100mcg inhalation powder (Green drug). 

This is licensed for the prevention and treatment of asthma in patients aged 6 years and over. Its addition provides an alternative dry powder inhalation device for patients who are unable to coordinate activation of a pressurised metered-dose inhaler. Novolizer is less expensive than other dry powder devices. Novolizer budesonide is of similar cost or slightly more expensive than breath-actuated inhalers. 

2.5. Uvistat UVB-SPF 50 cream (Green drug)

This item is used for photoprotection and is not a licensed medicine. Nevertheless, it is classified as a borderline substance and regarded as a drug when prescribed for skin protection in abnormal cutaneous photosensitivity.  
 
 
 

3.0 Items/brands to be deleted from the Prescribed List with three months notice 

3.1. Items to be deleted

3.1.1. Beclometasone CFC-containing MDI 50mcg, 100mcg, 200mcg, 250mcg

3.1.2. Chlordiazepoxide tablets 5mg, 10mg

3.1.3. Didronel PMO 

3.2. Items to be listed as Generic only with three months notice 

3.2.1. Clarithromycin tablets 250mg, 500mg

3.2.2. Co-cyprindiol tablets

3.2.3. Co-dydramol tablets 10/500mg

3.2.4. Colchicine tablets 250mcg, 500mcg

3.2.5. Cyproterone tablets 50mg

3.2.6. Haloperidol capsules 500mg; tablets 1.5mg, 5mg, 10mg

3.2.7. Imipramine tablets 10mg, 25mg

3.2.8. Meloxicam tablets 7.5mg, 15mg

3.2.9. Oxybutynin tablets 2.5mg, 5mg

3.2.10. Paracetamol tablets 500mg; soluble tablets 500mg

3.2.11. Pergolide tablets 50mcg, 250mcg, 1mg

3.2.12. Pizotifen 500mcg, 1.5mg

3.2.13. Prednisolone tablets 1mg, 5mg; e/c tablets 2.5mg, 5mg

3.2.14. Risperidone liquid 1mg/mL; tablets  1mg, 2mg, 3mg, 4mg, 6mg

3.2.13. Spironolactone tablets 25mg, 50mg, 100mg

3.2.14. Sumatriptan tablets 50mg, 100mg

3.2.15.Tramadol capsules 50mg

3.2.16. Zopiclone tablets 3.75mg, 7.5mg

3.2.17. Zolpidem tablets 5mg, 10mg 

4. RECOMMENDATION 

The Minister is asked to approve all other changes to take effect from 1st October 2008. 
 
 

  Livelink ® Version 9.2.0, Copyright © 1995-2003 Open Text Inc. All rights reserved.

 

 

Back to top
rating button